In this interview, Karim Fizazi, MD, PhD, of the University of Paris-Sud, Orsay, France gives an overview of the LATITUDE study (NCT01715285), which investigated whether patients with newly diagnosed metastatic prostate cancer would benefit from combination therapy involving abiraterone acetate, low-dose prednisone and androgen deprivation therapy. Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting in Chicago, IL, Prof. Fizazi outlines the progress LATITUDE has made and the overall promising results of the study.
LATITUDE: combination therapy for newly diagnosed prostate cancer
